Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Journal of Hypertension

• Publication date

  1996-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00004872-199612000-00003PMID 8986921
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Changes in left ventricular inflow and pulmonary venous flow velocities during preload alteration in hypertrophic cardiomyopathy.

  1996cited by this paper
• Evaluation of left ventricular diastolic hemodynamics from the left ventricular inflow and pulmonary venous flow velocities in hypertrophic cardiomyopathy.

  1995cited by this paper
• Angiotensin-converting enzyme I/D polymorphism and arterial wall thickness in a general population. The Vobarno Study.

  1995cited by this paper
• Angiotensin-converting enzyme polymorphism and essential hypertension.

  1994cited by this paper
• Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus.

  1994cited by this paper
• Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy.

  1994cited by this paper
• DD Genotype of the Angiotensin‐Converting Enzyme Gene Is a Risk Factor for Left Ventricular Hypertrophy

  1994cited by this paper
• Tissue renin-angiotensin system in myocardial hypertrophy and failure.

  1993cited by this paper
• Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death.

  1993cited by this paper
• A potent genetic risk factor for restenosis

  1993cited by this paper
• Association analysis of a polymorphism of the angiotensin converting enzyme gene with essential hypertension in the Japanese population.

  1993cited by this paper
• Polymorphism of the angiotensin I converting enzyme gene is apparently not related to high blood pressure: Dutch Hypertension and Offspring Study

  1993cited by this paper
• Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy.

  1993cited by this paper
• The angiotensin I converting enzyme gene and predisposition to high blood pressure.

  1993cited by this paper
• Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes.

  1993cited by this paper
• Identification of Functional Angiotensin II Receptors on Rat Cardiac Fibroblasts

  1993cited by this paper
• Association of a polymorphism of the angiotensin I-converting enzyme gene with essential hypertension.

  1992cited by this paper
• Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction

  1992cited by this paper
• Increase of angiotensin converting enzyme gene expression in the hypertensive aorta.

  1992cited by this paper
• PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1).

  1992cited by this paper
• Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System

  1991cited by this paper
• Assessment of left ventricular relaxation by Doppler echocardiography. Comparison of isovolumic relaxation time and transmitral flow velocities with time constant of isovolumic relaxation.

  1990cited by this paper
• An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.

  1990cited by this paper
• Familial resemblance of plasma angiotensin-converting enzyme level: the Nancy Study.

  1988cited by this paper
• Muscle fiber orientation and connective tissue content in the hypertrophied human heart.

  1982cited by this paper
• Colorimetry of angiotensin-I converting enzyme activity in serum.

  1981cited by this paper
• Echocardiographic Determination of Left Ventricular Mass in Man: Anatomic Validation of the Method

  1977cited by this paper
• Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy.

  1976cited by this paper

• Correlation Between Angiotensin-Converting Enzyme Insertion/Deletion Gene Polymorphism and the Co-Occurrence of Left Ventricular Hypertrophy in Patients with Hypertension.

  2025cites this paper
• PHARMACOGENETICS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACEI) AND ANGIOTENSIN II RECEPTOR BLOCKERS (ARB) IN CARDIOVASCULAR DISEASES.

  2024cites this paper
• Pharmacogenomics Informs Cardiovascular Pharmacotherapy.

  2022cites this paper
• Pharmacogenetics to Avoid Adverse Reactions in Cardiology: Ready for Implementation?

  2021cites this paper
• Association between angiotensin converting enzyme gene polymorphism and essential hypertension: A systematic review and meta-analysis

  2021cites this paper
• Antiremodeling Efficacy of Zofenopril in Patientswith Arterial Hypertension Taking into Account I/D Polymorphism of the ACE Gene

  2020cites this paper
• PGPM_A_230201 341..359

  2019cites this paper
• Pharmacogenomics And Hypertension: Current Insights

  2019cites this paper
• The effect of angiotensin-converting enzyme polymorphism on hemodynamic response to endotracheal intubation in hypertensive patients

  2016cites this paper
• A Physiologic Approach to the Pharmacogenomics of Hypertension.

  2016cites this paper
• PHARMACOGENOMICS AND PERSONALIZED MANAGEMENT OF HYPERTENSION

  2015cites this paper
• Role of ACE I/D gene polymorphisms on the effect of ramipril in inflammatory response and myocardial injury in patients undergoing coronary artery bypass grafts

  2014cites this paper
• Cardiovascular pharmacogenetics of antihypertensive and lipid- lowering therapies.

  2014cites this paper
• Pharmacogenetics and Cardiovascular Disease—Implications for Personalized Medicine

  2013cites this paper
• Hunting the Risk NPY and ACE Polymorphisms as Predictors of Cardiovascular Diseases: Case Report and Review of the Literature

  2013cites this paper
• Untersuchung von myokardialen Verletzungen und ventrikulärer Funktion bei Marathonläufern in Abhängigkeit von genetischen Parametern

  2012cites this paper
• Angiotensin-converting enzyme gene deletion allele increases the risk of left ventricular hypertrophy: evidence from a meta-analysis

  2012cites this paper
• Angiotensin Converting Enzyme Gene Insertion/Deletion Polymorphism and Cardiovascular Disease

  2012cites this paper
• Association of echocardiographic left ventricular structure with the ACE D/I polymorphism: a meta-analysis

  2011cites this paper
• Genetic variation in the renin—angiotensin system, use of renin—angiotensin system inhibitors and the risk of myocardial infarction

  2011cites this paper
• Genetic polymorphisms related to the renin–angiotensin–aldosterone system and response to antihypertensive drugs

  2010cites this paper
• PharmGKB summary: very important pharmacogene information for angiotensin-converting enzyme

  2010cites this paper
• Beneficial effects of telmisartan on left ventricular structure and function in patients with hypertension determined by two-dimensional strain imaging

  2009cites this paper
• Significance of genetic polymorphisms of the renin-angiotensin-aldosterone system in cardiovascular and renal disease.

  2009cites this paper
• The D allele of angiotensin I-converting enzyme gene insertion/deletion polymorphism is associated with the severity of atherosclerosis

  2008cites this paper
• Genetic polymorphism, medical therapy and sequential cardiac function in patients with heart failure.

  2008cites this paper
• Interactions between a dducin 2 and antihypertensive drug therapies in determining blood pressure in hypertensives

  2007cites this paper
• Interactions between the adducin 2 gene and antihypertensive drug therapies in determining blood pressure in people with hypertension

  2007cites this paper
• Exploring design-related bias in clinical studies on receptor genetic polymorphism of hypertension.

  2007cites this paper
• Genetics of arterial hypertension and hypotension

  2007cites this paper
• Association between genetic polymorphisms of the prostaglandin F2alpha receptor gene and response to latanoprost.

  2007cites this paper
• Are All the Hypertensives Made Equal?

  2006cites this paper
• Massa cardíaca e função do ventrículo esquerdo em amostra da população brasileira: genes candidatos

  2006cites this paper
• β2‐Adrenergic receptor polymorphisms and treatment‐induced regression of left ventricular hypertrophy in hypertension

  2006cites this paper
• Molecular Pathogenesis of Cardiovascular Disease

  2006cites this paper
• Polymorphisms in cardiovascular medicine: the role of genetic variants in disease diagnosis and drug response

  2006cites this paper
• Future Pharmacologic Agents for Treatment of Heart Failure in Children

  2006cites this paper
• T1198C Polymorphism of the Angiotensinogen Gene and Antihypertensive Response to Angiotensin-Converting Enzyme Inhibitors

  2005cites this paper
• A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril

  2005cites this paper
• Angiotensin-converting enzyme gene deletion polymorphism modulation of onset of symptoms and survival rate of patients with heart failure.

  2005cites this paper
• Hypertension pharmacogenomics: current status and future directions.

  2005cites this paper
• Gene markers and antihypertensive therapy

  2005cites this paper
• Pharmacogenetic Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Antihypertensive Treatment: The Genetics of Hypertension-Associated Treatment (GenHAT) Study

  2005cites this paper
• [Individual sensitivity to antihypertensive drugs: genetic aspects].

  2005cites this paper
• Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy

  2005cites this paper
• Effect of 24-Week Treatment with Telmisartan on Myocardial Structure and Function: Relationship to Insertion/Deletion Polymorphism of the Angiotensin-Converting Enzyme Gene

  2005cites this paper
• Mortality in patients with hypertension on angiotensin-I converting enzyme (ACE)-inhibitor treatment is influenced by the ACE insertion/deletion polymorphism

  2005cites this paper
• Pharmacogenomics of blood pressure response to antihypertensive treatment

  2005cites this paper
• Pharmacogenomics of Antihypertensive Treatment a Clinical Pharmacological Studies of Digoxin Treatment

  2005cites this paper
• Relation to Antihypertensive Treatment : The Genetics of Insertion / Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Pharmacogenetic Association of the Angiotensin-Converting Enzyme

  2005cites this paper
• Vascular effects of quinapril completely depend on ACE insertion/deletion polymorphism

  2004cites this paper
• Multiple Polymorphisms in the Renin- Angiotensin-Aldosterone System (ACE, CYP11B2, AGTR1) and Their Contribution to Hypertension in African Americans and Latinos in the Multiethnic Cohort

  2004cites this paper
• Pharmacogenetics of Antihypertensive Drug Responses

  2004cites this paper
• Losartan improves regional left ventricular systolic and diastolic function in patients with hypertension: accurate evaluation using a newly developed color-coded tissue doppler imaging technique.

  2004cites this paper
• Studies of the G protein beta 3 subunit in human hypertension

  2004cites this paper
• The Genetic Basis of Essential Hypertension and Its Implications for Treatment

  2004cites this paper
• Relationship between ACE-DD polymorphism and diastolic performance in healthy subjects

  2004cites this paper
• Genes That Modify Susceptibility to Atherosclerosis: Targets for Drug Action

  2004cites this paper
• Pharmacogenomics of left ventricular hypertrophy reversal: beyond the 'one size fits all' approach to antihypertensive therapy.

  2004cites this paper
• Untersuchung zum Einfluß des ACE Gen Polymorphismus auf die Entwicklung einer linksventrikulären Hypertrophie bei Patienten mit terminaler Niereninsuffizienz.

  2004cites this paper
• Drug-Gene Interactions between Genetic Polymorphisms and Antihypertensive Therapy

  2004cites this paper
• Over-expression of angiotensin converting enzyme-1 augments cardiac hypertrophy in transgenic rats.

  2004cites this paper
• Relationship between polymorphism of the angiotensin-converting enzyme gene and the response to angiotensin-converting enzyme inhibition in hypertensive patients.

  2003cites this paper
• [I/D gene polymorphism of the angiotensin-converting enzyme and left ventricular hypertrophy. Response to converting enzyme inhibitors].

  2003cites this paper
• [Role of angiotensin-converting enzyme gene polymorphism in the development of metabolic syndrome].

  2003cites this paper
• Pharmacogenomics: marshalling the human genome to individualise drug therapy

  2003cites this paper
• Polymorphisms in the RAS and cardiac function.

  2003cites this paper
• Pharmacogenomics--drug disposition, drug targets, and side effects.

  2003cites this paper
• Pharmacogenetic Studies of Antihypertensive Treatment

  2002cites this paper
• ACE genotype and ACE inhibitor response in kidney disease: a perspective.

  2002cites this paper
• Angiotensin converting enzyme DD genotype is associated with hypertensive crisis*

  2002cites this paper
• Pharmacogenetics and cardiovascular disease: impact on drug response and applications to disease management.

  2002cites this paper
• Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial

  2002cites this paper
• Pharmacogenomics: the future of drug therapy

  2002cites this paper
• Improving Cardiovascular drug Therapy Through Pharmacogenomics

  2002cites this paper
• Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study

  2002cites this paper
• Genetic determinants of the stress response in cardiovascular disease.

  2002cites this paper
• The drive to identify genetic factors influencing left ventricular mass responses to antihypertensive treatment.

  2002cites this paper
• The angiotensin-converting enzyme gene I/D polymorphism and heart rate variability following acute myocardial infarction

  2002cites this paper
• Pharmacogenomics: unlocking the human genome for better drug therapy.

  2001cites this paper
• Drug Target Pharmacogenomics

  2001cites this paper
• Antihypertensive pharmacogenetics: getting the right drug into the right patient.

  2001cites this paper
• Pharmacogenomics: the inherited basis for interindividual differences in drug response.

  2001cites this paper
• Pharmacogenomics of childhood acute lymphoblastic leukemia.

  2001cites this paper
• Pharmacogenetic Studies of Antihypertensive Treatment : With Special Reference to the Renin-Angiotensin-Aldosterone System

  2001cites this paper
• Effects of Antihypertensive Agents on the Left Ventricle

  2001cites this paper
• Genetics of Hypertension

  2001cites this paper
• Drug target pharmacogenomics: an overview.

  2001cites this paper
• Usefulness of the I/D angiotensin-converting enzyme genotype for detecting the risk of left ventricular hypertrophy in pharmacologically treated hypertensive men

  2000cites this paper
• Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine.

  2000cites this paper
• Antihypertensive treatment modulates the association between the D/I ACE gene polymorphism and left ventricular hypertrophy: a meta-analysis

  2000cites this paper
• Angiotensin I-Converting Enzyme Gene Polymorphism and Drug Response

  2000cites this paper
• Predicting Response to Chronic Antihypertensive Treatment with Fosinopril: The Role of Angiotensin-Converting Enzyme Gene Polymorphism

  2000cites this paper
• Lack of Association of Angiotensin-converting Enzyme and Angiotensinogen Genes Polymorphisms with Left Ventricular Structure in Young Normotensive Men

  2000cites this paper
• Subendocardial motion in hypertrophic cardiomyopathy: assessment from long- and short-axis views by pulsed tissue Doppler imaging.

  2000cites this paper
• Angiotensin I-Converting Enzyme Genotype and Disease Associations

  2000cites this paper
• THE EFFECTS OF MONOTHERAPY OR COMBINED THERAPY WITH AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR FOLLOWING INITIAL TREATMENT WITH CALCIUM CHANNEL BLOCKERS ON RESIDUAL CARDIOVASCULAR ABNORMALITIES

  2000cites this paper
• Synergistic effect of angiotensin-converting enzyme and angiotensinogen gene on cardiac hypertrophy.

  2000cites this paper
• The interface between pharmacoepidemiology and pharmacogenetics.

  2000cites this paper
• Renin-angiotensin system gene polymorphisms: potential mechanisms for their association with cardiovascular diseases.

  2000cites this paper